Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes
暂无分享,去创建一个
[1] Salim Yusuf,et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.
[2] B. Eliasson,et al. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. , 2012, Primary care diabetes.
[3] G. Steineck,et al. Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation , 2012, Acta oncologica.
[4] A. Pariente,et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database , 2012, Diabetologia.
[5] J. Coebergh,et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study , 2011, Diabetologia.
[6] J. Skinner,et al. Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer , 2011, Diabetes Care.
[7] M. Lai,et al. Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study , 2011, PloS one.
[8] S. Suissa,et al. Long-term effects of insulin glargine on the risk of breast cancer , 2011, Diabetologia.
[9] G. Steineck,et al. Insulin glargine use and short-term incidence of malignancies — a three-year population-based observation , 2011, Acta oncologica.
[10] D. Balzi,et al. Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients , 2010, Diabetes Care.
[11] P. Home,et al. Combined randomised controlled trial experience of malignancies in studies using insulin glargine , 2009, Diabetologia.
[12] H. Colhoun,et al. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.
[13] G. Steineck,et al. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden , 2009, Diabetologia.
[14] E. Gale,et al. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.
[15] L. Hemkens,et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study , 2009, Diabetologia.
[16] D. Nathan. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.
[17] the Scottish Diabetes Research Network Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.
[18] B. Davies,et al. European Association for the Study of Diabetes , 1984 .
[19] H. Grosse. [Diabetes and cancer]. , 1956, Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten.